Patents by Inventor Cameron Brandt
Cameron Brandt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11952408Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.Type: GrantFiled: September 28, 2018Date of Patent: April 9, 2024Assignees: Juno Therapeutics, Inc., Editas Medicine, Inc.Inventors: Cameron Brandt, Brian Belmont, Christopher Borges, Stephen Michael Burleigh, Alexandra Croft, Stephen Jacob Goldfless, David Jeffrey Huss, Yue Jiang, Timothy G. Johnstone, David Koppstein, Hieu Nguyen, Christopher Heath Nye, Haley Peper, Blythe D. Sather, Sonia Timberlake, Dean Y. Toy, Queenie Vong, Gordon Grant Welstead, James Sissons
-
Publication number: 20230256018Abstract: Provided herein are binding molecules, such as those that recognize or bind a peptide epitope of a cancer antigen, such as expressed on a cancer cell, including cells infected with human papilloma virus (HPV) or that contain HPV DNA sequences and/or those that recognize or bind a peptide epitope of HPV 16 E6 or E7, in the context of a major histocompatibility complex (MHC) molecule. Among the provided binding molecules are T cell receptors (TCRs) or antibodies, including antigen-binding fragments thereof, that bind or recognize such peptide epitopes. The present disclosure further relates to engineered cells comprising such binding molecules, e.g., TCRs or antibodies (and chimeric antigen receptors containing the antibodies), and uses thereof in adoptive cell therapy.Type: ApplicationFiled: June 30, 2022Publication date: August 17, 2023Applicant: Juno Therapeutics, Inc.Inventors: Stephen Jacob GOLDFLESS, Brian BELMONT, Cameron BRANDT, Alexandra CROFT, David Jeffrey HUSS
-
Patent number: 11471489Abstract: Provided herein are binding molecules, such as those that recognize or bind a peptide epitope of a cancer antigen, such as expressed on a cancer cell, including cells infected with human papilloma virus (HPV) or that contain HPV DNA sequences and/or those that recognize or bind a peptide epitope of HPV 16 E6 or E7, in the context of a major histocompatibility complex (MHC) molecule. Among the provided binding molecules are T cell receptors (TCRs) or antibodies, including antigen-binding fragments thereof, that bind or recognize such peptide epitopes. The present disclosure further relates to engineered cells comprising such binding molecules, e.g., TCRs or antibodies (and chimeric antigen receptors containing the antibodies), and uses thereof in adoptive cell therapy.Type: GrantFiled: April 3, 2019Date of Patent: October 18, 2022Assignee: Juno Therapeutics, Inc.Inventors: Stephen Jacob Goldfless, Brian Belmont, Cameron Brandt, Alexandra Croft, David Jeffrey Huss
-
Publication number: 20210363258Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV16 E6 and HPV16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.Type: ApplicationFiled: July 23, 2021Publication date: November 25, 2021Applicant: Juno Therapeutics, Inc.Inventors: James SISSONS, Cameron Brandt, Alexandra Croft, Allen Ebens, Haley Peper, Dean Y. Toy
-
Publication number: 20210284709Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.Type: ApplicationFiled: September 28, 2018Publication date: September 16, 2021Applicants: Juno Therapeutics, Inc., Editas Medicine, Inc.Inventors: Cameron BRANDT, Brian BELMONT, Christopher BORGES, Stephen Michael BURLEIGH, Alexandra CROFT, Stephen Jacob GOLDFLESS, David Jeffrey HUSS, Yue JIANG, Timothy G. JOHNSTONE, David KOPPSTEIN, Hieu NGUYEN, Christopher Heath NYE, Haley PEPER, Blythe D. SATHER, Sonia TIMBERLAKE, Dean Y. TOY, Queenie VONG, Gordon Grant WELSTEAD, James SISSONS
-
Patent number: 11072660Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.Type: GrantFiled: October 3, 2017Date of Patent: July 27, 2021Assignee: Juno Therapeutics, Inc.Inventors: James Sissons, Cameron Brandt, Alexandra Croft, Allen Ebens, Haley Peper, Dean Y. Toy
-
Publication number: 20190321401Abstract: Provided herein are binding molecules, such as those that recognize or bind a peptide epitope of a cancer antigen, such as expressed on a cancer cell, including cells infected with human papilloma virus (HPV) or that contain HPV DNA sequences and/or those that recognize or bind a peptide epitope of HPV 16 E6 or E7, in the context of a major histocompatibility complex (MHC) molecule. Among the provided binding molecules are T cell receptors (TCRs) or antibodies, including antigen-binding fragments thereof, that bind or recognize such peptide epitopes. The present disclosure further relates to engineered cells comprising such binding molecules, e.g., TCRs or antibodies (and chimeric antigen receptors containing the antibodies), and uses thereof in adoptive cell therapy.Type: ApplicationFiled: April 3, 2019Publication date: October 24, 2019Applicant: Juno Therapeutics, Inc.Inventors: Stephen Jacob GOLDFLESS, Brian BELMONT, Cameron BRANDT, Alexandra CROFT, David Jeffrey HUSS
-
Publication number: 20190225692Abstract: Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.Type: ApplicationFiled: October 3, 2017Publication date: July 25, 2019Applicant: Juno Therapeutics, Inc.Inventors: James SISSONS, Cameron BRANDT, Alexandra CROFT, Allen EBENS, Haley PEPER, Dean Y. TOY, Brian BELMONT, Stephen GOLDFLESS, Yue JIANG, Timothy JOHNSTONE, David KOPPSTEIN, Hieu NGUYEN, Blythe SATHER, Sonia TIMBERLAKE
-
Publication number: 20070254339Abstract: The present invention relates to a method of preparing a tetrameric protein comprising culturing a host cell transformed or transfected with an expression vector encoding a fusion protein comprising a vasodialator-stimulated phosphoprotein (VASP) domain and a heterologous protein. In one embodiment, the heterologous protein is a membrane protein, the portion of the heterologous protein that included in the fusion protein is the extracellular domain of that protein, and the resulting fusion protein is soluble. The method can be used to produced homo- and hetero-tetrameric proteins. The present invention also encompasses DNA molecules, expression vectors, and host cells used in the present method and fusion proteins produced by the present method.Type: ApplicationFiled: April 13, 2007Publication date: November 1, 2007Inventors: James West, Cameron Brandt
-
Publication number: 20070054360Abstract: The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.Type: ApplicationFiled: May 12, 2006Publication date: March 8, 2007Inventors: Zeren Gao, Steven Levin, Janine Bilsborough, James West, Cameron Brandt, Frederick Ramsdell, Edward Howard, Erick Chadwick
-
Publication number: 20060286092Abstract: Novel methods of using isolated polypeptides, isolated polynucleotides encoding the polypeptides, and related compositions are disclosed for pNKp30 protein. The methods involved modulating the proliferation of T-cells in vitro and in vivo and modulation of immune response. The present invention also includes methods for producing pNKp30, including soluble molecules, uses therefor and antibodies thereto.Type: ApplicationFiled: May 12, 2006Publication date: December 21, 2006Inventors: Zeren Gao, Steven Levin, Christopher Clegg, Jane Gross, Wenfeng Xu, Frederick Ramsdell, Cameron Brandt
-
Publication number: 20060263851Abstract: A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.Type: ApplicationFiled: July 18, 2006Publication date: November 23, 2006Inventors: Donald Foster, Wenfeng Xu, Karen Madden, James Kelly, Cindy Sprecher, Cameron Brandt, Mark Rixon, Scott Presnell, Brian Fox
-
Publication number: 20060263850Abstract: A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.Type: ApplicationFiled: July 18, 2006Publication date: November 23, 2006Inventors: Donald Foster, Wenfeng Xu, Karen Madden, James Kelly, Cindy Sprecher, Cameron Brandt, Mark Rixon, Scott Presnell, Brian Fox
-
Publication number: 20050009149Abstract: The present invention provides methods for producing trimeric tumor necrosis factor receptors that are potent inhibitors of their cognate ligands.Type: ApplicationFiled: October 10, 2003Publication date: January 13, 2005Inventors: James West, Cameron Brandt, Stephen Jaspers
-
Publication number: 20050003475Abstract: A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.Type: ApplicationFiled: December 22, 2000Publication date: January 6, 2005Inventors: Donald Foster, Wenfeng Xu, Karen Madden, James Kelly, Cindy Sprecher, Cameron Brandt, Mark Rixon, Scott Presnell, Brian Fox